Previously, we determined that the recombinant CRT fragment 39-272 (CRT/39-272), which lacks the C-terminus and KDEL motif, exhibited potent immunostimulatory activity and strong adjuvanticity, and soluble CRT/39-272 (sCRT/39-272) promoted tumor malignancy through TLR4- and S100A8/9-mediated myeloid-derived suppressor cell (MDSC) differentiation and recruitment [24]. Here, CALR is linked to neoplasm.